Do BPC-157 or TB-500 cause cancer?

This is not known, in the literal sense. For BPC-157, no carcinogenicity study has ever been conducted, and it has never been measured whether an existing tumor grows faster under the substance. For TB-500, incriminating animal data exist for the body's own parent protein, but from an experimental setup that differs from actual use. The data allow neither an all-clear nor a solid statement about whether a risk exists and how large it would be. Mechanistic, animal-experimental, and human-genetic findings do support that the question is legitimate. Conversely, though, there is also no finding that has actually shown accelerated tumor growth: not in the one animal study that also measured tumor sizes, not in the human studies of other vessel-forming procedures that excluded people with active cancer from the outset, and not in the form of a published case report.

Does BPC-157 really promote angiogenesis?

Yes, that is documented in several models. It upregulates the receptor VEGFR2 and activates the VEGFR2-Akt-eNOS cascade, shown in the chick chorioallantoic membrane, in human endothelial cells, and in a rat ischemia model (PMID 27847966). All the evidence comes from healing or blood-flow models, none from a tumor model.

Has BPC-157 ever been tested in a tumor model?

Only a single findable study used tumor-bearing animals: mice with a colon carcinoma, examined for cachexia. Tumor volume was numerically lower, the difference was not statistically significant, and the study was not designed to answer this question (PMID 29898649). A study specifically designed to test tumor growth under BPC-157 does not exist.

Why should TB-500 be assessed differently from BPC-157?

Because the parent protein thymosin beta-4 has a real cancer literature. It is elevated in several human tumor types, and in a mouse melanoma model, overexpression promoted tumor size and lung metastases, while knockout in colon cancer cells slowed tumor growth. Nothing was reported on metastasis in the knockdown model. This body of data simply does not exist for BPC-157.

What does the distinction between the body's own production and injection mean?

In the incriminating experiments, the tumor cell produces the protein itself and thereby acts on itself and its surroundings. With TB-500, by contrast, it is about supplying a short synthetic fragment from outside. Whether the same effect on a tumor follows from that has never been investigated. In the studies that come closest to supply from outside, the full recombinant protein was given, not the TB-500 fragment, and there, tumor growth was even lower, depending on the model.

Do human studies show that promoting angiogenesis triggers cancer?

In cardiac medicine, new vessel formation has been deliberately stimulated. A study with 103 patients over a mean of 8.1 years found 1, 4, and 2 cancer cases in the three groups, with no significant difference (PMID 19212427); another over a median of eleven years likewise found no signal (PMID 31288177). These studies are small, however: they involved cardiovascular patients, cancer was captured only incidentally, and people with a known active cancer were excluded from the outset. A given risk cannot be reliably ruled out on this basis.

Is there evidence that systemic VEGF promotes cancer in humans?

A human genetic analysis found a causal association between lifelong higher VEGF levels and colorectal cancer (OR 1.21; confidence interval 1.11 to 1.32), specific to this cancer type and not as a general rule (PMID 36159967). This does not translate directly, since it concerns lifelong genetic predisposition, not a time-limited administration of a substance.

Can an angiogenic stimulus wake a dormant tumor?

In a mouse model, dormant, poorly perfused tumor cells began to grow after an angiogenic stimulus was applied in their immediate vicinity for a few days (PMID 16537511). The stimulus there was local and directly adjacent, not systemically administered, and the host was immunocompromised. It is the strongest animal finding in favor of the concern, and yet still not directly transferable.

Did the FDA reject BPC-157 because of cancer risk?

Not according to the published justification documents. The conclusion of the FDA experts cites four reasons: inadequate characterization, immunogenicity risk from aggregation and impurities, lack of efficacy evidence for the indication applied for, and manufacturing questions. Cancer, tumor, and angiogenesis are not named there as reasons. This is explicitly not a statement of safety regarding cancer risk. The responsible advisory committee, incidentally, did not follow this recommendation and voted 8 to 6 for inclusion, though only in an advisory, non-binding capacity.

Was a study halted due to cancer concerns?

There is no evidence for that. The only registered human study of BPC-157 is listed in the public register as unknown, last updated in 2015, with no published results and no documented reason for discontinuation. The cancer explanation is therefore unsubstantiated, but so is every other specific explanation.

What applies if there is a history of cancer?

This is a medical question, not a research question, and it belongs with the treating physicians who know the specific findings. We sell exclusively research material and cannot and must not make any recommendation on this.

Does a lack of evidence mean it is safe?

No. Missing data is not an all-clear, it is simply missing data. For BPC-157, the question was never asked, neither in a carcinogenicity study, nor in a tumor model, nor in humans. Anyone who infers safety from this is confusing not knowing with being safe.

Should the combination of both substances be assessed differently?

There is no dedicated data on the combination. The data on the individual substances still applies. Whether the effects amplify, weaken, or change nothing at all in combination has not been studied. For this combination, no data whatsoever exists with respect to tumors.

What can actually be checked when a safety question is open?

Above all, the material quality: that a batch contains what is on the label, and that purity is documented. Certificates of analysis are available for our batches, each assigned to the batch number and viewable via our CoA overview. This does not answer the cancer question, but it does reduce a separate uncertainty, to the extent of the attributes actually tested in each case.

Why do online statements differ so much?

Because the same thin body of data is weighted differently. Anyone who foregrounds the mechanism arrives at a recommendation for caution; anyone who emphasizes the lack of evidence for actual tumor growth arrives at an all-clear. Only the cautious reading, though, is actually consistent with the data: missing data is not a clean bill of health, because the decisive study was simply never conducted.

Do BPC-157 and TB-500 Promote Tumors? What the Angiogenesis Research Shows

Q: Is it true that BPC-157 inhibited melanoma cells?

This claim comes from a 2004 conference abstract that was never published as a full paper, is not findable in PubMed, and has never been replicated. The accompanying claim of reduced lung metastases in mice is still described as unpublished by the original group itself, as of 2025. This does not qualify as reassurance.

In short: what the evidence actually shows

The concern is mechanistically grounded. BPC-157 demonstrably activates pro-angiogenic signaling pathways, and tumors need new blood vessels. This is not internet panic, it is a logical question.

But it has never been specifically investigated. No published study was designed to test whether BPC-157 makes an existing tumor grow faster. In no species. There is also no carcinogenicity study.

With TB-500, the case is different. For thymosin beta-4, the parent molecule, real oncology literature exists. The decisive distinction there is one that is almost never mentioned: the incriminating findings come from tumor cells that produce the protein themselves, not from an injection from outside.

The FDA did not cite cancer as a reason for rejection. We searched the full text of the justification documents. The four reasons stated in the conclusion concern characterization, immunogenicity, evidence of efficacy, and manufacturing. Cancer and angiogenesis do not appear there as reasons.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

TB-500regeneration

Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.

WOLVERINE (BPC-157 + TB-500)regeneration

The Wolverine Stack: BPC-157 + TB-500 in equal parts in one vial (50/50: 10mg = 5mg each, 20mg = 10mg each). The most researched healing peptide duo for tissue repair, tendon recovery, and systemic regeneration. Batch-specific Janoshik COA.

Healing & Regenerationregeneration

Tissue repair, wound healing, and recovery peptides

Why the Question Is Legitimate

The same consideration keeps coming up in research forums, and it is cleanly stated: both substances promote the formation of new blood vessels. A tumor that wants to grow beyond a few millimeters has to achieve exactly the same thing. So anyone who sets a systemic pro-angiogenic signal may be doing some of the work for a tumor that happens to be present.

This consideration is not biologically far-fetched, and it deserves an honest answer rather than a reassuring one. Especially because the people who ask it often have a concrete history: an excised early-stage melanoma, a thyroid nodule awaiting biopsy, a family history.

What this article cannot do

This text presents the state of the evidence. It is not medical advice and cannot be. If there is a history of cancer, if a finding is being worked up, or if a suspicion is on the table, that question belongs with the treating physicians who know the findings. Our peptides are exclusively research material and not intended for use in humans.

What BPC-157 Demonstrably Does, and Where It Was Measured

The angiogenic effect is real and has been described repeatedly. It is also the reason these substances are researched at all: new blood vessels are the precondition for injured tissue to be supplied and repaired, and it is exactly in such models that BPC-157 shows its most consistent findings. What matters, then, is which models the measurements were made in.

The most detailed mechanistic work shows that BPC-157 increases vessel density in the chick chorioallantoic (egg) membrane, increases tube formation in human endothelial cells, and accelerates blood-flow recovery in a rat model with an occluded leg artery. Molecularly, it specifically upregulates the receptor VEGFR2, not its messenger VEGF-A itself, and activates the VEGFR2-Akt-eNOS cascade (PMID 27847966).

A second finding, often conflated with the first, describes something different: in the isolated rat aorta, BPC-157 dilates vessels via a Src-caveolin-1-eNOS pathway that is explicitly VEGF-independent (PMID 33051481). What was measured there was vessel width, not new vessel formation. Anyone who cites both papers as the same mechanism is blurring a real distinction.

Then there is wound healing: in a burn model on rat skin, BPC-157 activates the ERK1/2 pathway in endothelial cells, along with the transcription factors c-Fos, c-Jun, and Egr-1 (PMID 25995620). In a rat tendon and muscle injury model, by contrast, new vessel formation was described via VEGF upregulation (PMID 20388964). The counter-regulation via NAB2 that is often cited alongside this could not be substantiated in any findable primary source; it appears only in manufacturer texts without a reference.

The pattern behind these studies

Injury, reduced blood flow, vessel tone. Every model is a healing or ischemia model in animals or cell culture. None of them includes a tumor. The mechanism is thus well described, but the context is entirely different from the one the concern is actually about.

The Real Gap: The Question Was Never Asked

After reviewing the findable literature, the verdict on BPC-157 is not "safe" and not "dangerous," but: untested.

There is no carcinogenicity study. The standard test that would answer this question is a typically two-year rodent study. Such a study has never been conducted for BPC-157.

There is also no study that was specifically designed to test tumor growth under BPC-157 against a control, in any cancer type. The only findable study in tumor-bearing animals examined mice with a colon carcinoma, but it was designed for cachexia, that is, weight loss. There, body weight and inflammatory markers improved significantly, and tumor volume was numerically lower under BPC-157 than in the untreated group, though without statistical significance (PMID 29898649). No sign of accelerated tumor growth was found there in any case.

In humans, an angiogenesis endpoint has never been assessed. The only human data on BPC-157 are a small phase 1 study on tolerability and pharmacokinetics and a small trial in ulcerative colitis, both only as conference abstracts and without a full publication.

Two pieces of evidence often cited as an all-clear, and what they really are

First, the melanoma finding: BPC-157 is said to have inhibited the growth of human melanoma cells. This comes from a 2004 conference abstract, was never published as a full paper, is not findable in PubMed, and has never been replicated. The accompanying claim of reduced lung metastases in mice is still labeled unpublished by the original group itself, as recently as 2025.

Second, the cachexia study: it is occasionally cited as evidence against tumor promotion. It was not designed for that purpose, and not even the research group behind BPC-157 cites it that way.

Both are weak pieces of evidence, and weak evidence of safety is not safety.

TB-500 Is a Different Case, and Here Lies the Most Important Distinction

Unlike BPC-157, thymosin beta-4, the body's own parent protein of TB-500, has an extensive cancer literature. It is elevated in several human tumor types, including colorectal carcinoma, thyroid tumors, GIST, and hepatoblastoma.

The causally acting animal experiments are clear: mouse melanoma cells induced to overproduce the full 43-amino-acid protein themselves produced larger tumors after 20 days (21.7 mm versus 13.3 mm) and roughly 4.3 times as many lung metastases (46.7 versus 10.9 nodules), mediated via increased angiogenesis (PMID 14625258). Conversely, knocking out the body's own thymosin beta-4 in colon cancer cells slowed tumor growth (PMID 25124811).

This is exactly where the distinction lies that is almost always missing from the discussion.

The tumor makes it itself, or it is injected from outside. That is not the same thing.

In the incriminating experiments, the tumor cell produces the protein itself and thereby acts on itself and its immediate surroundings. That is a signal that arises continuously within the tumor.

With TB-500, by contrast, it is about supplying a short synthetic fragment from outside. Whether the same biological effect on a tumor follows from that has never been tested.

What is notable is what happens in the studies where the protein was given from outside. There, the full recombinant protein was used, not the fragment marketed as TB-500. In a lung cancer model, tumor growth was lower with more thymosin beta-4, and likewise in a myeloma model. Across the literature, the direction is therefore not consistent: overexpression within the tumor itself pointed one way, supply from outside pointed the other.

To date, no study has been conducted in a tumor-bearing organism using the fragment actually marketed as TB-500 itself.

Does the Basic Premise Even Hold?

The reasoning goes: pro-angiogenic, therefore tumor-promoting. This premise, too, deserves scrutiny, and the answer is mixed.

In favor: dormant, poorly perfused tumor cells in mice began to grow after an angiogenic stimulus was applied in their immediate vicinity for a few days, in immunocompromised animals (PMID 16537511). Mice with permanently overexpressed VEGF developed tumors earlier and died earlier, though metastasis did not increase (PMID 11809716). And a human genetic analysis found a causal association between lifelong higher VEGF levels and colorectal cancer (OR 1.21; 95% confidence interval 1.11 to 1.32), though specific to this cancer type (PMID 36159967).

Against it speak the limited human findings from three small follow-up studies: in cardiovascular medicine, new vessel formation was deliberately stimulated for years to improve blood flow. In a study with 103 patients and a mean follow-up of 8.1 years, 1, 4, and 2 cancer cases occurred in the three groups respectively, with no significant difference (PMID 19212427). In a study with 52 patients over a median of eleven years, two people died of cancer in the placebo group and none in the treatment group, again without statistical significance (P = 0.17; PMID 31288177), and a third study with 30 patients over just over eight years used cancer as a predefined safety endpoint and reported a safety profile comparable to placebo (PMID 34593990). So in none of the three studies did what the concern would suggest actually occur.

Why this all-clear only holds to a limited extent

These studies included 30 to 103 people. Cancer was nowhere the primary endpoint; it was only captured incidentally. They found no signal, but because of their size and the secondary endpoint, they do not permit a reliable statement about what level of risk can be ruled out.

Above all, though: these were cardiovascular patients without a known active cancer, which was excluded at study entry. So they do not test the case this article is actually about, namely a tumor that is already present or not yet detected.

What Is Claimed About the FDA, and What the Documents Actually Say

It is often said that the FDA's rejection was due to cancer concerns. We searched the full text of the advisory committee's justification documents.

For BPC-157, the recommendation from the FDA experts cites four reasons: inadequate physicochemical characterization, immunogenicity risk from aggregation and impurities in the injectable form, lack of efficacy evidence for the indication applied for, and manufacturing questions. In this conclusion, cancer, tumor, and angiogenesis are not named as reasons. That does not mean the documents never touch on the topic anywhere, and it is certainly not a clean bill of health.

What is notable is what happened next: the responsible advisory committee did not follow its own experts' recommendation, but voted 8 to 6 to place BPC-157 on the list. For thymosin beta-4, the vote came out with the same majority. This vote is advisory and not binding. It concerned inclusion on a manufacturing list, not the cancer question.

In the document on TB-500, under the heading Carcinogenicity, there is a note that no data are available or were submitted. What stands out, though, is something else: the extensive independent oncology literature on thymosin beta-4 is not addressed there at all. That is a gap in the review, not an acquittal.

Also widespread is the narrative that a study was halted due to cancer concerns. The only registered human study of BPC-157 is listed in the public register as "unknown," last updated in 2015, with no published results. No reason for discontinuation is documented anywhere. The cancer explanation is therefore unsubstantiated, but so is every other specific explanation.

And the often-cited case report?

A targeted literature search found not a single published case report in which a tumor arose, progressed, or recurred under BPC-157 or TB-500.

That is worth mentioning, but it proves little. A case report requires a treating clinician to notice the connection, consider it worth reporting, and pursue publication. With freely purchased research material that is often not even mentioned to physicians, this chain is rarely complete.

What Is Claimed Online, and What It Is Based On

The following section does not judge anyone. It simply places side by side what is stated in publicly accessible video titles, descriptions, and accompanying articles on this topic, and what the source linked there actually contains. Video content itself cannot be technically verified, so the comparison relies exclusively on material available in writing: titles, descriptions, accompanying articles, and one official episode transcript. The sources looked up are those linked in such texts on this topic. This section makes no statement about their reach or about what is said in the videos themselves.

Claim: The angiogenic mechanism of BPC-157 poses a possible tumor growth risk, which is why caution is warranted for anyone with a corresponding concern. This account comes from a widely followed science podcast. The source behind it: In the official episode transcript, the statement is explicitly framed as a theoretical consideration derived from wound-healing research. No tumor study of BPC-157 is claimed there. The account, then, is consistent with what the research actually supports.

Claim: BPC-157 is wrongly suspected of a cancer risk, in part because it is said to have inhibited melanoma cell growth. The source behind it: A two-page 2004 conference abstract on a single melanoma cell line. It was never published as a full paper, is not listed in PubMed, and has never been replicated in two decades. The accompanying figure on reduced lung metastases in mice is still described as unpublished by the original group itself, as of 2025.

Claim: A 2020 review article documents the substance's safety profile. The source behind it: The paper is a mechanistic and conceptual review on the topic of cytoprotection. It does not contain carcinogenicity data or toxicological studies.

Claim: Common vitamins are also angiogenic, so the argument against BPC-157 is unfair. The source behind it: The cited 2017 review article on vitamins and angiogenesis exists and is accurately represented. However, it says nothing about BPC-157 and describes the vitamin effects more cautiously than the citing source does.

In parallel, the scholarly debate has long been playing out in the literature, and there it is conducted with the cards on the table. In 2025, the journal Pharmaceuticals published an exchange between Jozwiak and colleagues and the research group around Sikiric. The latter explicitly disputes the risk hypothesis: they argue that BPC-157 shows antitumoral potential in their work and steers new vessel formation rather than driving it indiscriminately, and they reject drawing tumor formation from angiogenesis (PMID 41155565). The other side counters that the evidence cited for this is exactly those unpublished and never-replicated studies. Anyone who wants to form their own opinion can find both positions in full text there.

Assessment

Anyone expecting a clear answer will be disappointed, and that is the honest state of things.

For BPC-157, it is this: pro-angiogenic, documented, but exclusively in healing models, never in a tumor study specifically designed for the question, never in humans. The question is open, not answered. Open here explicitly means in both directions: to date, there is no finding that has shown tumor growth under BPC-157, neither from an animal study nor from a case report.

For TB-500, it is this: for the body's own parent protein, there are incriminating animal data, but from an experimental setup that differs systematically from supplying it from outside. Where the full protein was given from outside, tumor growth was lower in both findable models.

For both, the same applies: anyone with a history of cancer, an unclear finding being worked up, or membership in a risk group is facing a medical question, not a research question. That decision belongs to the people who know the specific findings.

What quality actually comes down to in this field

With an open safety question, what remains verifiable is above all the material quality itself: that a batch contains what is on the label, and that purity is documented. Certificates of analysis are available for our batches, each assigned to the specific batch number and viewable via the CoA overview. This does not answer the cancer question, but it does reduce a separate uncertainty, exactly to the extent of the quality attributes documented there.

Individual Peptides